OVID Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ovid Therapeutics Inc is not a strong buy for a beginner, long-term investor at this moment. The technical indicators show a neutral to bearish trend, and the financial performance is weak with declining revenue, net income, and EPS. While analysts have provided positive ratings and higher price targets, the lack of recent news, hedge fund selling, and no significant insider activity diminish immediate confidence. Additionally, Intellectia Proprietary Trading Signals show no strong buy signals today.
The MACD histogram is negative (-0.00477) and expanding, indicating bearish momentum. The RSI is neutral at 39.601, and moving averages are converging, suggesting no clear trend. Key support is at 1.436, and resistance is at 1.638. The stock is trading below the pivot level of 1.537, which is a bearish signal.
Analysts have given positive ratings with price targets ranging from $2 to $5, citing the potential of OV329 and the epilepsy market's need for new therapies.
Hedge funds are selling heavily, with a 668.25% increase in selling activity last quarter. Financial performance is weak, with declining revenue (-23.70% YoY), net income (-13.19% YoY), and EPS (-15.00% YoY). No recent news or congress trading data is available to support a positive sentiment.
In Q3 2025, revenue dropped to $132,000 (-23.70% YoY), net income fell to -$12.16M (-13.19% YoY), and EPS declined to -0.17 (-15.00% YoY). Gross margin remained stable at 100%.
Analysts have provided positive ratings with price targets ranging from $2 to $5. They highlight the potential of OV329 as a differentiated therapy in the epilepsy market and the favorable regulatory environment for new drugs.
